Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H13N3OS |
| Molecular Weight | 307.37 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=CN3N=CC(C4=CSC=C4)=C3N=C2
InChI
InChIKey=HBWLNACPIFKNIP-UHFFFAOYSA-N
InChI=1S/C17H13N3OS/c1-21-15-4-2-12(3-5-15)14-8-18-17-16(9-19-20(17)10-14)13-6-7-22-11-13/h2-11H,1H3
| Molecular Formula | C17H13N3OS |
| Molecular Weight | 307.37 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. | 2002 Dec 16 |
|
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | 2013 Apr 15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:04:08 UTC 2023
by
admin
on
Sat Dec 16 08:04:08 UTC 2023
|
| Record UNII |
FHX0K077F6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
216661-57-3
Created by
admin on Sat Dec 16 08:04:08 UTC 2023 , Edited by admin on Sat Dec 16 08:04:08 UTC 2023
|
PRIMARY | |||
|
DTXSID90416191
Created by
admin on Sat Dec 16 08:04:08 UTC 2023 , Edited by admin on Sat Dec 16 08:04:08 UTC 2023
|
PRIMARY | |||
|
FHX0K077F6
Created by
admin on Sat Dec 16 08:04:08 UTC 2023 , Edited by admin on Sat Dec 16 08:04:08 UTC 2023
|
PRIMARY | |||
|
5329468
Created by
admin on Sat Dec 16 08:04:08 UTC 2023 , Edited by admin on Sat Dec 16 08:04:08 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
